Open AccessGemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life‐saving treatment
Author(s) -
Gosain Rahul,
Gill Amitoj,
Fuqua Jacob,
Volz Lesley H.,
Kessans Knable Mika R.,
Bycroft Ryan,
Seger Sarah,
Gosain Rohit,
Rios Jorge A.,
Chao JuHsien
Publication year - 2017
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.1214
Subject(s) - carfilzomib , medicine , eculizumab , thrombotic microangiopathy , adverse effect , gemcitabine , compassionate use , intensive care medicine , drug , oncology , pharmacology , bortezomib , chemotherapy , multiple myeloma , complement system , immunology , clinical trial , antibody , disease
Key Clinical Message Drug‐induced aHUS is rare; however, early diagnosis is vital to reduce morbidity and mortality. With confirmation of the diagnosis, eculizumab appears to be a viable treatment option to suppress the pro‐inflammatory surge. Furthermore, adverse side effects of medications such as carfilzomib and gemcitabine should be considered in the appropriate settings.